SFI
CAPR icon

Susquehanna Fundamental Investments’s Capricor Therapeutics CAPR Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-16,500
Closed -$85K – 1711
2021
Q2 		$85K Sell
16,500
-15,900
-49% -$67.4K ﹤0.01% 1583
2021
Q1 		$152K Buy
+32,400
New +$187K ﹤0.01% 1424
2020
Q4 		– Sell
-16,125
Closed -$85K – 1504
2020
Q3 		$85K Sell
16,125
-11,375
-41% -$66.3K ﹤0.01% 1297
2020
Q2 		$127K Buy
+27,500
New +$120K 0.01% 889

Other funds holding CAPR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Susquehanna Fundamental Investments's CAPR Position: Q3 2021 in Review

Susquehanna Fundamental Investments sold out of Capricor Therapeutics (CAPR) in Q3 2021, closing a stake of 16,500 shares — an estimated $85K sold.

Susquehanna Fundamental Investments first reported a position in CAPR in Q2 2020 and held it in 4 quarters. The position peaked at $152K in Q1 2021. 30 funds tracked by Wall St. Rank hold CAPR as of Q3 2021.

  • Susquehanna Fundamental Investments reported no remaining Capricor Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 16,500 Capricor Therapeutics shares in Q3 2021, an estimated $85K.
  • Susquehanna Fundamental Investments first reported a position in Capricor Therapeutics in Q2 2020 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's Capricor Therapeutics position peaked at $152K in Q1 2021.
  • 30 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2021, filed 15 Nov 2021.